Details checkedStrong evidenceCheckedcompany

AOK-1

Also known as: AOK-1, regeneration injection

Boehringer Ingelheim

Primary source

Company

Boehringer Ingelheim

Program Type

Therapeutic

Modality

Regenerative Medicine

Stage

Preclinical

Status

Active

Target Gene

—

Route / Mode

Middle-ear injection

Confidence

82%

Status Confidence

Status confirmed

Evidence Strength

Strong evidence

Last Reviewed

2026-05-31

Geography

United States, Germany

Population

adult, age-related, noise-induced

Trial IDs

Mechanism

siRNA nanoparticle therapeutic is intended to reprogram supporting cells and regenerate cochlear hair cells.

Indications

Hearing Loss Sensorineural Hearing Loss Age-Related Hearing Loss Noise-Induced Hearing Loss

Notes

One of the more credible hair-cell-regeneration concepts outside public biotech; licensed into a Boehringer-linked collaboration via Autigen.

Evidence & Sources

3 structured sources

company

Supports: canonicalName, aliases, mechanism, indications, route, status

IDs: AOK-1

Open

company

Supports: company, allCompanies, stage, notes

IDs: AOK-1, Autigen

Open

company

Supports: mechanism, notes

IDs: AOK-1

Open

Key Events

2022-04-13

Autigen announced collaboration and license agreement with Boehringer Ingelheim for hearing-loss therapies

Related Programs

Otarmeni by Regeneron

Company: Regeneron Pharmaceuticals · Gene Therapy · Approved

PEDMARK by Fennec Pharmaceuticals

Company: Fennec Pharmaceuticals · Small Molecule · Marketed

AK-OTOF by Eli Lilly and Akouos

Company: Eli Lilly and Company · Gene Therapy · Phase 2

SENS-401 (Arazasetron) by Sensorion

Company: Sensorion · Small Molecule · Phase 2

SENS-501 by Sensorion

Company: Sensorion · Gene Therapy · Phase 1/2

Rincell-1 by Rinri Therapeutics

Company: Rinri Therapeutics · Cell Therapy · Phase 1/2